<DOC>
	<DOCNO>NCT02127476</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics KHK6640 , give single dose multiple dos patient Prodromal Alzheimer 's Disease ( AD ) Mild Moderate AD .</brief_summary>
	<brief_title>A Study Single Multiple Doses KHK6640 Subjects With Prodromal Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients prodromal AD mild moderate AD Clinical Dementia Rating ( CDR ) score 0.5 , 1.0 , 2.0 Have cognitive impairment Low AÎ² high Tau Cerebrospinal fluid ( CSF ) Mini Mental State Examination ( MMSE ) score &gt; 16 Screening Previous active treatment AD immunotherapy investigational study Use another investigational drug within 30 day screen History presence clinically significant seizure , brain trauma , transient ischemic attack , and/or cerebrovascular disease Presence neurological condition could contribute cognitive impairment beyond cause subject 's AD Evidence infection , tumor , clinically significant lesion could indicate dementia diagnosis AD</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>